BioSpace

After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce

Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include dissolution and liquidation.

By BioSpace

1 min read
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights